Rapport Therapeutics: CEO Ceesay Abraham sold 4,522 shares

What happened Ceesay Abraham, CEO, sold 3,375 shares on Oct 6, 2026 at a weighted average price of $32.03 for $108,106, and sold 1,147 shares on Oct 7, 2026 at a weighted average price of $30.66 for $35,167, for total proceeds of $143,273. The filings report these as open-market or private sales (Code S).

Key details

• Transaction dates and prices: Oct 6, 2026 — 3,375 shares at $32.03 (weighted avg) for $108,106; Oct 7, 2026 — 1,147 shares at $30.66 (weighted avg) for $35,167.
• Shares owned after the transactions: not reported in this filing.
• Footnotes: transactions were effected pursuant to Rule 10b5-1 trading plans adopted on Mar 27, 2026 (F1). The reported prices are weighted averages; Oct 6 sales occurred at prices ranging from $31.65 to $32.64 (F2) and Oct 7 sales at prices ranging from $30.33 to $30.89 (F3). The reporting person will provide per-price breakdowns upon request.
• Filing date: Form 4 filed on Oct 8, 2026. No late filing is indicated in the Form 4.

Why it may matter These were open-market sales executed under Rule 10b5-1 trading plans. A filing does not show why the insider traded or why the company acted.